DAT+/TH+ monocyte populations in AD patients are indistinguishable from healthy controls, leading us to conclude that increased numbers of monocytes expressing markers of dopamine signaling are not general to all neurodegenerative diseases. This evidence concerns the gene SLC6A3 and Alzheimer disease.